Gartner’s Hype Cycle predicts that, following initial enthusiasm, emerging technologies must endure waning interest (before ultimately recovering) as early experiments fail to deliver on inflated expectations. Apart from a few striking success stories, cancer cell therapies have largely disappointed in the clinic, and stock prices have underperformed as a result. While additional future clinical and commercial wins are no doubt in the offing, those tasked with development of these technologies must inflect value and raise funds within challenging present-day market conditions.
Join us for a sober assessment (supported by recent market data) of the challenges facing oncology cell therapy companies as the field moves from platform/preclinical promise to clinical and commercial reality. After laying out the state of play, we’ll identify some implications and strategic considerations for these ambitious companies grappling with high burn rates, limited relief from (or need for) Pharma partners, and mounting skepticism among public and private investors.
– Historical trends impacting cancer cell therapy companies over the past few years
– Forward-looking implications for companies and other key stakeholders (investors, clinicians) in this market- Opportunities for collaboration
Joel Sandler, PhD, Principal, BioConsulting, Cancer Cell Therapy Lead, Central Nervous System Co-Lead, Lumanity
Michael DeRidder, PhD, SVP, Corporate Strategy and New Product Planning, Catamaran Bio
Ajla Hrle, Head of Life Science, Family Office
Michael Kalos, Managing Director, Next Pillar Consulting
Paul Lammers, MD, MSc, President, CEO, Triumvira Immunologics